Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia

J Pediatr Hematol Oncol. 2001 Dec;23(9):609-11. doi: 10.1097/00043426-200112000-00011.

Abstract

Numerous children have been treated successfully for cancer and are surviving into adulthood. As this population has aged, an increasing number of secondary malignancies has emerged. Renal cell carcinoma (RCC) is a rare tumor in childhood and has not been documented previously to occur after treatment of acute promyelocytic leukemia (APL). This report describes the clinical course of APL treated in a child in whom RCC subsequently developed during adolescence approximately 5 years after therapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Renal Cell / etiology*
  • Cerebral Infarction / etiology
  • Child
  • Chromosomes, Human, Pair 17 / genetics
  • Combined Modality Therapy
  • Cranial Irradiation
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Dexamethasone / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Hypertension / complications
  • Kidney Failure, Chronic / chemically induced
  • Leukemia, Promyelocytic, Acute / complications
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics
  • Leukemia, Promyelocytic, Acute / radiotherapy
  • Male
  • Neoplasms, Second Primary / etiology*
  • Obesity / complications
  • Remission Induction
  • Thioguanine / administration & dosage

Substances

  • Cytarabine
  • Etoposide
  • Dexamethasone
  • Thioguanine
  • Daunorubicin